On Friday, Shares of Alibaba Group Holding Limited (NYSE:BABA), lost -0.47% to $74.76.
Alibaba Group Holding Ltd. dominates the Chinese e-commerce market, but it increasingly is watching its back, thanks to a swarm of industry newcomers, according to WSJ.
The clearest threat is from JD.com Inc., a longtime rival. Indeed, in China their rivalry has earned the nickname “the great cat and dog war”—referring to the respective mascots of Alibaba’s Tmall website and JD.com. WSJ Reports
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally.
Shares of Exelon Corporation (NYSE:EXC), inclined 1.01% to $33.08, during its last trading session.
Energy supplier Constellation declared that it is expanding its home services business into Texas. Constellation Home will provide a one-stop shop for homeowners in the Dallas and Houston areas for heating, cooling, plumbing and water heater solutions to fit their home and budget.
As part of the launch, Constellation Home is introducing its “peace of mind” no-deductible Home Protection Plan.* The plan provides customers coverage on home system repairs such as heating and air conditioning, water heaters, and in-home electrical, in addition to unlimited service calls from local, certified technicians.
Eligible customers who enroll in a StarTex Power fixed-rate electricity plan during the launch will receive 12 months of in-home electric line protection, allowing them to lock in a competitive electric supply rate, while protecting their budget from unpredictable home electrical systems repairs.
Baltimore-based Constellation is a partner of Exelon Corporation (EXC), the nation’s leading competitive energy provider, with 2014 revenues of about $27.4 billion, and more than 32,000 megawatts of owned capacity comprising one of the nation’s cleanest and lowest-cost power generation fleets.
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
Finally, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ended its last trade with 1.83% gain, and closed at $11.68.
BioCryst Pharmaceuticals declared financial results for the second quarter ended June 30, 2015.
Second Quarter Financial Results
For the three months ended June 30, 2015, revenues raised to $25.8 million from $1.5 million in the second quarter of 2014. Revenue in the quarter was primarily due to the partial recognition of the upfront payment to BioCryst resulting from the licensing of RAPIVAB(R) (peramivir injection), in addition to a noteworthy enhance in partnership revenue associated with BCX4430 development as a medical countermeasure for Ebola virus and other filovirus diseases.
Research and development expenses for the quarter raised to $16.5 million from $11.1 million in the second quarter of 2014. The enhance in 2015 R&D expenses, as contrast to 2014, was the result of raised R&D expenses associated with the Company’s HAE and BCX4430 development programs. The more substantial enhance was related to development expenses associated with the HAE portfolio and resulted from higher spending for continued development of avoralstat, formerly known as BCX4161, and expenses for second generation compound development, counting BCX7353.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
